By: ABRS- Clinical Insights Team
Abstract
Decentralized clinical trials (DCTs) are transforming the clinical research landscape by enabling remote participation, expanding patient access, and increasing operational flexibility. However, this shift from traditional site-based models to distributed trial execution introduces new challenges in maintaining data integrity, ensuring consistent oversight, and meeting regulatory expectations.
As data is increasingly generated through digital tools, remote assessments, and multiple external stakeholders, organizations must adapt their operational frameworks to ensure that data remains reliable, traceable, and inspection-ready. This article explores the key challenges associated with decentralized trials, focusing on data integrity risks, operational complexity, and the need for robust governance to support compliant and high-quality trial execution.
Introduction
The clinical research landscape is undergoing a significant transformation as decentralized elements become more widely adopted across clinical trials. Remote visits, digital health technologies, and direct-to-patient approaches are enabling more flexible and patient-centric study designs, reducing geographic barriers and supporting broader participation.
While these advancements offer clear benefits, they also represent a fundamental shift in how clinical trials are conducted. Traditional models relied on controlled, site-based environments where data collection, monitoring, and oversight were centralized. In contrast, decentralized trials distribute these activities across multiple locations, systems, and stakeholders, creating a more complex operational ecosystem.
This transition raises important questions around how to maintain consistency, control, and data reliability in environments that are inherently less centralized. As organizations continue to adopt decentralized approaches, there is a growing need to ensure that innovation is supported by strong governance, clear accountability, and operational frameworks that align with regulatory expectations.
Understanding how to balance flexibility with control will be critical as decentralized clinical trials continue to evolve and become a standard component of clinical development strategies.
From Centralized Control to Distributed Execution
Decentralized clinical trials are reshaping how clinical research is executed by moving selected trial activities beyond traditional site-based settings. Remote visits, home health services, digital data capture, and direct-to-participant processes can improve flexibility and patient access, but they also require stronger operational coordination to preserve trial quality.
The FDA emphasizes that the use of decentralized elements does not change the fundamental responsibilities of sponsors and investigators. Even when trial-related activities occur remotely or through third parties, sponsors must ensure appropriate oversight, participant safety, and reliable data collection throughout the study (U.S. Food and Drug Administration [FDA], 2024).
This shift creates a more distributed execution model, where data may be generated across multiple environments, systems, and stakeholders. A 2025 recommendation paper published in Therapeutic Innovation & Regulatory Science highlights that advancing decentralized elements requires careful planning around operational feasibility, technology integration, stakeholder coordination, and regulatory alignment to ensure that decentralization supports—not compromises—trial quality (Marcano et al., 2025).
In this context, decentralized execution should not be viewed simply as a convenience strategy. It represents a structural change in clinical trial operations, requiring organizations to maintain clear accountability, documented processes, and consistent oversight across every point where trial data is generated or handled.
Data Integrity in Remote Data Collection
The expansion of decentralized clinical trials introduces new complexities in maintaining data integrity, particularly as data is increasingly generated outside traditional clinical sites. Remote data collection through digital health technologies, wearables, and patient-reported outcomes requires careful control to ensure that data remains accurate, complete, and attributable throughout its lifecycle. Unlike site-based data capture, decentralized models rely on multiple systems and environments, increasing the risk of inconsistencies if governance and validation processes are not robustly implemented.
Regulatory guidance underscores the importance of maintaining the same standards of data reliability regardless of where trial activities occur. The FDA highlights that sponsors must ensure that data collected through decentralized approaches is suitable for regulatory evaluation, with appropriate controls over data capture, handling, and monitoring (U.S. Food and Drug Administration [FDA], 2024). This includes ensuring that technologies used for remote data acquisition are fit for purpose and that processes are in place to maintain data quality across all trial activities.
From an operational perspective, ensuring data integrity in decentralized environments requires more than system validation—it demands a comprehensive governance framework. Industry analysis emphasizes that organizations must implement strong controls over data flow, establish clear audit trails, and ensure traceability from data origin to final analysis, particularly when integrating data from multiple digital sources (Medidata, 2025). This becomes increasingly critical as patient-generated data and real-time monitoring tools are incorporated into trial designs.
As decentralized models continue to evolve, maintaining data integrity will depend on an organization’s ability to align technology, processes, and oversight. Without this alignment, the benefits of remote data collection may be offset by increased variability, regulatory risk, and challenges in demonstrating data reliability during inspections.
Operational Complexity and Oversight in Decentralized Models
While decentralized clinical trials offer clear advantages in terms of flexibility and patient access, they also introduce a higher level of operational complexity that must be actively managed. Trial activities are no longer confined to a single site but distributed across multiple stakeholders, technologies, and geographic locations. This shift increases the number of data sources, handoffs, and dependencies, all of which can impact consistency, quality, and oversight if not properly coordinated.
Regulatory expectations remain consistent despite this increased complexity. The FDA emphasizes that sponsors are responsible for ensuring appropriate oversight of all trial-related activities, including those conducted by third parties or through decentralized approaches. This includes maintaining control over processes, ensuring protocol adherence, and verifying that data collected across different settings remains reliable and suitable for regulatory review (U.S. Food and Drug Administration [FDA], 2024).
From an industry and academic perspective, the expansion of decentralized elements requires stronger cross-functional coordination and more structured operational planning. A 2025 analysis in Therapeutic Innovation & Regulatory Science highlights that successful implementation of decentralized trials depends on effectively managing technology integration, aligning stakeholders, and ensuring consistent execution across diverse operational environments (Marcano et al., 2025). Without this alignment, variability across regions, vendors, and systems can introduce risks that affect both data quality and trial timelines.
To address these challenges, organizations must move toward more integrated oversight models that combine clinical, operational, and technological governance. This includes clearly defined roles and responsibilities, standardized processes across vendors, and centralized visibility into trial activities. As decentralized trials continue to scale globally, the ability to manage operational complexity will be a key determinant of both compliance and overall trial success.
Regulatory Readiness and Inspection Implications
As decentralized clinical trials continue to evolve, regulatory readiness is becoming a central concern—particularly in how organizations demonstrate control over distributed processes during inspections. Unlike traditional trials, where oversight is largely site-centric, decentralized models require regulators to assess data and processes that span multiple systems, vendors, and locations. This increases the importance of traceability, documentation, and demonstrable control across the entire data lifecycle.
Regulatory guidance reinforces that all trial data, regardless of how it is collected, must be fit for purpose and verifiable during inspection. The FDA underscores that sponsors must ensure adequate oversight of decentralized activities, including those performed by third parties, and must be able to demonstrate that processes are controlled and consistently executed (U.S. Food and Drug Administration [FDA], 2024). This places greater emphasis on documentation practices, audit trails, and the ability to reconstruct trial activities when required.
From a data integrity perspective, inspection readiness in decentralized trials depends heavily on the ability to maintain end-to-end visibility and control over data flows. Industry analysis highlights that organizations must implement structured frameworks to ensure data is attributable, traceable, and protected against unauthorized changes, particularly when integrating data from multiple digital sources and platforms (Medidata, 2025). This becomes especially critical when dealing with remote data capture, where variability in devices, environments, and user behavior can introduce additional risk.
In this context, inspection readiness is no longer a downstream activity but an ongoing operational requirement. Organizations must proactively design decentralized trials with compliance in mind—ensuring that governance, validation, and oversight mechanisms are embedded from the outset. Those that can demonstrate consistent control across decentralized processes will be better positioned to meet regulatory expectations and support successful trial outcomes.
Conclusion
The clinical research landscape is undergoing a significant transformation as decentralized elements become more widely adopted across clinical trials. Remote visits, digital health technologies, and direct-to-patient approaches are enabling more flexible and patient-centric study designs, reducing geographic barriers and supporting broader participation.
While these advancements offer clear benefits, they also represent a fundamental shift in how clinical trials are conducted. Traditional models relied on controlled, site-based environments where data collection, monitoring, and oversight were centralized. In contrast, decentralized trials distribute these activities across multiple locations, systems, and stakeholders, creating a more complex operational ecosystem.
This transition raises important questions around how to maintain consistency, control, and data reliability in environments that are inherently less centralized. As organizations continue to adopt decentralized approaches, there is a growing need to ensure that innovation is supported by strong governance, clear accountability, and operational frameworks that align with regulatory expectations.
Understanding how to balance flexibility with control will be critical as decentralized clinical trials continue to evolve and become a standard component of clinical development strategies.
References
Marcano, A. I., et al. (2025). Recommendation paper on advancing the use of decentralised elements in clinical trials. Therapeutic Innovation & Regulatory Science.
https://link.springer.com/content/pdf/10.1007/s43441-025-00796-w.pdf
Medidata. (2025). Data integrity.
https://www.medidata.com/wp-content/uploads/2025/05/WHITEPAPER-Data-Integrity.pdf
U.S. Food and Drug Administration. (2024). Conducting clinical trials with decentralized elements: Guidance for industry.
https://www.fda.gov/media/167696/download
U.S. Food and Drug Administration. (2024). Conducting clinical trials with decentralized elements (Federal Register notice).
https://www.govinfo.gov/content/pkg/FR-2024-09-18/pdf/2024-21078.pdf
